Posted by Michael Wonder on 06 Nov 2022
HLB's US subsidiary scores FDA fast track designation for Merkel cell cancer vaccine
4 November 2022 - HLB said on Friday that the anti-cancer vaccine candidate ITI-3000 aiming to treat Merkel cell cancer via its US subsidiary Immunomic Therapeutics has received fast track designation by the FDA.
ITI-3000 is an anticancer vaccine made by combining lysosomal-associated membrane protein 1 (LAMP1) with the large T antigen of the polyomavirus based on the vaccine platform, UNITE.
